Scrofuloderma following BCG vaccination.
Atasoy
Mustafa
M
Aliağaoğlu
Cihangir
C
Erdem
Teoman
T
Ozdemir
Sevki
S
Aktaş
Akin
A
D000995:Antitubercular Agents / Q000627:therapeutic use; D001500:BCG Vaccine / Q000009:adverse effects*; D002648:Child; D005260:Female; D006801:Humans; D007538:Isoniazid / Q000627:therapeutic use; D011718:Pyrazinamide / Q000627:therapeutic use; D012293:Rifampin / Q000627:therapeutic use; D012867:Skin / Q000187:drug effects / Q000473:pathology; D013307:Streptomycin / Q000627:therapeutic use; D016896:Treatment Outcome; D014382:Tuberculosis, Cutaneous / Q000188:drug therapy / Q000209:etiology*
D000995:Antitubercular Agents; D001500:BCG Vaccine; D011718:Pyrazinamide; D007538:Isoniazid; D012293:Rifampin; D013307:Streptomycin